Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bosentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 0.98 |
| ▸ | EDNRB known ✓ | P24530 | 12/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | DHPS | P49366 | 1/20 | 0.98 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.98 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bosentan SCHEMBL29620398 | 1.00 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL4218 | 0.99 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL29485039 | 0.99 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL3981779 | 0.99 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL902870 | 0.99 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL615991 | 0.98 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL628837 | 0.98 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL979668 | 0.98 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL977683 | 0.98 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| Bosentan SCHEMBL2723442 | 0.98 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4045143-B1 | BOSENTAN MONOHYDRATE LOADED LIQUID SELF NANOEMULSIFYING DRUG CARRIER SYSTEM AND TABLET FORMULATION | GAZI UNIV (TR) | 2025-04-16 | — | — | EP | claimed |
| EP-4221689-A1 | FORMULATIONS OF BOSENTAN MONOHYDRATE LOADED SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEMS (SNEDDS) PREPARED WITH LONG-CHAIN MONO AND DIGLYCERIDE MIXTURES | Gazi University (TR) | 2023-08-09 | — | — | EP | claimed |
| EP-4045143-A2 | BOSENTAN MONOHYDRATE LOADED LIQUID SELF NANOEMULSIFYING DRUG CARRIER SYSTEM AND TABLET FORMULATION | Gazi University (TR) | 2022-08-24 | — | — | EP | claimed |
| WO-2022108572-A1 | FORMULATIONS OF BOSENTAN MONOHYDRATE LOADED SELF-NANOEMULSIFYING DRUG DELIVERY SYSTEMS (SNEDDS) PREPARED WITH LONG-CHAIN MONO AND DIGLYCERIDE MIXTURES | GAZI UNIVERSITY (TR) | 2022-05-27 | — | — | WO | claimed |
| WO-2021076081-A2 | BOSENTAN MONOHYDRATE LOADED LIQUID SELF NANOEMULSIFYING DRUG CARRIER SYSTEM AND TABLET FORMULATION | TEKSIN ZEYNEP SAFAK (TR) | 2021-04-22 | — | — | WO | claimed |
| WO-2020022546-A1 | PHARMACEUTICAL PREPARATION CONTAINING BOSENTAN | 주식회사 마더스제약 | 2020-01-30 | — | — | WO | claimed |
| EP-2621909-B1 | PROCESS FOR PREPARING BOSENTAN MONOHYDRATE AND ITS INTERMEDIATES | ZACH SYSTEM SPA (IT) | 2018-12-19 | — | — | EP | claimed |
| EP-2603497-B1 | A NOVEL PROCESS FOR PREPARATION OF BOSENTAN | MEGAFINE PHARMA P LTD (IN) | 2018-08-08 | — | — | EP | claimed |
| CN-103153964-B | The method preparing Bosentan monohydrate and intermediate thereof | ZACH系统股份公司 | 2016-10-05 | — | — | CN | claimed |
| EP-2406235-B1 | PROCESS FOR THE PREPARATION OF BOSENTAN | SIFAVITOR S R L (IT) | 2016-08-10 | — | — | EP | claimed |
| EP-2603497-A1 | A NOVEL PROCESS FOR PREPARATION OF BOSENTAN | Megafine Pharma (P) Ltd. (IN) | 2013-06-19 | — | — | EP | claimed |
| CN-103153964-A | Process for preparing bosentan monohydrate and its intermediates | ZACH SYSTEM SPA | 2013-06-12 | — | — | CN | claimed |
| CN-102600094-A | Bosentan sustained-release matrix tablet and preparation method thereof | XI AN LIBANG PHARMACEUTICAL CO LTD | 2012-07-25 | — | — | CN | claimed |
| WO-2012041764-A1 | PROCESS FOR PREPARING BOSENTAN MONOHYDRATE AND ITS INTERMEDIATES | ZACH SYSTEM S.P.A. (IT) | 2012-04-05 | — | — | WO | claimed |
| WO-2012020421-A1 | A NOVEL PROCESS FOR PREPARATION OF BOSENTAN | MEGAFINE PHARMA (P) LTD. (IN) | 2012-02-16 | — | — | WO | claimed |
| US-20120041200-A1 | PROCESS FOR THE PREPARATION OF BOSENTAN | SIFAVITOR S.R.L. (IT) | 2012-02-16 | — | — | US | claimed |
| EP-2406235-A2 | PROCESS FOR THE PREPARATION OF BOSENTAN | Sifavitor S.r.l. (IT) | 2012-01-18 | — | — | EP | claimed |
| WO-2011024056-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF BOSENTAN | AUROBINDO PHARMA LIMITED (IN) | 2011-03-03 | — | — | WO | claimed |
| WO-2011021216-A2 | IMPROVED PROCESS FOR THE PREPARATION OF 4-(1,1-DIMETHYLETHYL)-N-[6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)[2,2'-BIPYRIMIDIN]-4-YL]BENZENESULFONAMIDE | MSN LABORATORIES LIMITED (IN) | 2011-02-24 | — | — | WO | claimed |
| WO-2010103362-A2 | PROCESS FOR THE PREPARATION OF BOSENTAN | SIFAVITOR S.R.L. (IT) | 2010-09-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041200-A1 | PROCESS FOR THE PREPARATION OF BOSENTAN | EDNRB, BDKRB2, EDNRA | EDNRA 3/4885EDNRB 1/4885ABCC3 3067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.